RxDoctor Payments Data

Linda Esquivel, MD

Family Medicine · San Antonio, TXNPI 1043342181

Payments from drug & device makers

$173,037in general payments, 2019–2025

Across 1,035 payments — averaging $167.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$158K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$940
  • Amgen$844
  • plus $6K from 54 others

What the payments were for

  • Travel & lodging$7385%
  • Food & beverage$15,35695%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK77$158,395
Novo Nordisk207$2,892
AstraZeneca98$1,962
AbbVie(2 entities)108$1,708
Lilly USA, LLC111$940
Amgen54$844
Merck38$500
Ironshore Pharmaceuticals Inc.26$438
Avanir Pharmaceuticals, Inc.25$423
Biohaven Pharmaceuticals, Inc.20$354
Abbott16$303
Astellas Pharma US Inc17$268
Sanofi-aventis U.S. LLC16$266
Pfizer21$261
Neos Therapeutics, LP9$201
Bayer15$199
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$196
Nestle Healthcare Nutrition Inc.12$191
Takeda Pharmaceuticals U.S.A., Inc.10$167
Boehringer Ingelheim9$145
Johnson & Johnson7$130
Exact Sciences6$127
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$126
Dexcom, Inc.7$123
Axsome Therapeutics, Inc.5$122
Sumitomo Pharma America, Inc.6$87
Amarin Pharma, Inc.5$83
Eisai Inc.4$83
Ultragenyx Pharmaceutical Inc.5$81
Novartis5$81
Sunovion Pharmaceuticals Inc.5$80
Coloplast2$72
Biohaven Pharmaceutical Holding Company Ltd.3$68
Teva Pharmaceuticals USA, Inc.4$66
Supernus Pharmaceuticals, Inc.4$59
Otsuka America Pharmaceutical, Inc.3$59
Nalpropion Pharmaceuticals LLC4$55
Esperion Therapeutics, Inc.4$54
Si-bone, Inc.1$50
Lucid Diagnostics Inc.1$50
Upsher-smith Laboratories LLC4$48
Shire North American Group Inc3$47
Currax Pharmaceuticals LLC3$46
Jazz Pharmaceuticals Inc.3$43
Corium, LLC3$43
Genentech USA, Inc.3$41
Bausch Health US, LLC2$33
Gilead2$32
Ironwood Pharmaceuticals, Inc1$30
Cequr Corporation2$28
Agios Pharmaceuticals, Inc.1$27
Althera Pharmaceuticals LLC2$26
Vistapharm, Inc.2$25
Philips North America LLC1$24
Phadia US Inc.1$24
Alk-abello, Inc1$21
Lundbeck LLC1$19
Lifescan, Inc.1$19
Nevro Corp.1$19
Revance Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,037 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$208,829
Medicare patients
472
Services billed
2,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide280$465,799
MounjaroTirzepatide159$243,026
IngrezzaValbenazine Tosylate12$105,190
FarxigaDapagliflozin Propanediol87$97,551
JanuviaSitagliptin Phosphate82$96,176
JardianceEmpagliflozin65$83,222
EliquisApixaban55$73,528
LinzessLinaclotide57$60,724
Tresiba Flextouch U-200Insulin Degludec45$55,224
TrulicityDulaglutide28$53,239
Synjardy XrEmpagliflozin/Metformin Hcl22$35,893
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$32,569
XareltoRivaroxaban28$31,825
MyrbetriqMirabegron47$31,582
ProliaDenosumab16$26,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,892$486,142292 claims
Lilly USA, LLCMounjaro, Trulicity$940$296,266187 claims
Boehringer IngelheimJardiance, Synjardy Xr$145$119,11487 claims
MerckJanuvia, Janumet Xr$500$114,20795 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,962$108,594103 claims
PfizerEliquis, Premarin$261$78,44570 claims
AbbVieLinzess, Restasis$1,708$69,89869 claims
Johnson & JohnsonXarelto$130$31,82528 claims
Astellas Pharma US IncMyrbetriq$268$31,58247 claims
AmgenProlia$844$26,76916 claims
GSKShingrix$158,395$3,81417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →